The universal CD19-targeted CAR-T cell product (UCART19) was produced following the simultaneous introduction of CAR and TCR knockout to prevent GVHD and CD52 suppression to induce resistance to anti-CD52 Ab to reduce the likelihood of UCART19 rejection in allogeneic T cells (202). Here, CD52 is linked to graft versus host disease.